Literature DB >> 7536454

Consistent presence of isochromosome 7q in hepatosplenic T gamma/delta lymphoma: a new cytogenetic-clinicopathologic entity.

C C Wang1, H F Tien, M T Lin, I J Su, C H Wang, S M Chuang, M C Shen, C H Liu.   

Abstract

Peripheral T-cell lymphoma (PTL), which is characterized by hepatosplenic presentation and the gamma/delta T-cell receptor (TCR) phenotype on the malignant cells, is a rare but distinct subtype of non-Hodgkin's lymphomas. Little is known about the chromosomal changes in these lymphomas. We report the cytogenetic analysis of three patients who had neoplastic proliferation of T gamma/delta cells in the spleen, bone marrow, and liver, but not in lymph nodes or skin. Isochromosome 7q and trisomy 8 were observed in all three patients. Isochromosome 7q as the sole abnormality has been previously reported in one patient with similar clinicopathologic features. It is suggested that i(7q) is a primary, nonrandom chromosomal abnormality in hepatosplenic T gamma/delta PTL.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536454     DOI: 10.1002/gcc.2870120302

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  12 in total

1.  Hepatosplenic and subcutaneous panniculitis-like gamma/delta T cell lymphomas are derived from different Vdelta subsets of gamma/delta T lymphocytes.

Authors:  G K Przybylski; H Wu; W R Macon; J Finan; D G Leonard; R E Felgar; J A DiGiuseppe; P C Nowell; S H Swerdlow; M E Kadin; M A Wasik; K E Salhany
Journal:  J Mol Diagn       Date:  2000-02       Impact factor: 5.568

2.  Hepatosplenic gammadelta T-cell lymphoma with ring chromosome 7, an isochromosome 7q equivalent clonal chromosomal aberration.

Authors:  Julia Tamaska; Emma Adam; Andras Kozma; Laszlo Gopcsa; Hajnalka Andrikovics; Attila Tordai; Gabriella Halm; Laszlo Bereczki; Eniko Bagdi; Laszlo Krenacs
Journal:  Virchows Arch       Date:  2006-08-29       Impact factor: 4.064

3.  Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma.

Authors:  Andreas Zettl; German Ott; Angela Makulik; Tiemo Katzenberger; Petr Starostik; Thorsten Eichler; Bernhard Puppe; Martin Bentz; Hans Konrad Müller-Hermelink; Andreas Chott
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

4.  Hepatosplenic T-cell lymphoma.

Authors:  Fahad I Alsohaibani; Maheeba A Abdulla; Mousa M Fagih
Journal:  Indian J Hematol Blood Transfus       Date:  2011-02-12       Impact factor: 0.900

5.  Analysis of hematopoietic stem cell transplant engraftment: use of loss or gain of microsatellite alleles to identify residual hematopoietic malignancy.

Authors:  Ming-Tseh Lin; Li-Hui Tseng; Katie Beierl; Shuko Harada; Michael J Hafez; James R Eshleman; Christopher D Gocke
Journal:  Diagn Mol Pathol       Date:  2011-12

6.  Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment.

Authors:  G S Falchook; F Vega; N H Dang; F Samaniego; M A Rodriguez; R E Champlin; C Hosing; S Verstovsek; B Pro
Journal:  Ann Oncol       Date:  2009-02-23       Impact factor: 32.976

Review 7.  Gamma-delta T-cell lymphomas.

Authors:  Claudio Tripodo; Emilio Iannitto; Ada Maria Florena; Carlo Ennio Pucillo; Pier Paolo Piccaluga; Vito Franco; Stefano Aldo Pileri
Journal:  Nat Rev Clin Oncol       Date:  2009-11-10       Impact factor: 66.675

Review 8.  Hepatosplenic T-cell lymphoma: a rare but challenging entity.

Authors:  Barbara Pro; Pamela Allen; Amir Behdad
Journal:  Blood       Date:  2020-10-29       Impact factor: 22.113

9.  Hepatosplenic T-cell lymphoma: a rare cause of hepatosplenomegaly.

Authors:  Ana Cristina Lladó; Ana Luisa Tomé; Maria Henrique; Pedro Farinha
Journal:  BMJ Case Rep       Date:  2014-07-10

10.  Integrative genomic and transcriptomic analysis identified candidate genes implicated in the pathogenesis of hepatosplenic T-cell lymphoma.

Authors:  Julio Finalet Ferreiro; Leila Rouhigharabaei; Helena Urbankova; Jo-Anne van der Krogt; Lucienne Michaux; Shashirekha Shetty; Laszlo Krenacs; Thomas Tousseyn; Pascale De Paepe; Anne Uyttebroeck; Gregor Verhoef; Tom Taghon; Peter Vandenberghe; Jan Cools; Iwona Wlodarska
Journal:  PLoS One       Date:  2014-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.